CHILDHOOD ASTHMA MANAGEMENT PROGRAM CONTINUATION STUDY/PHASE 2

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。该方案用于儿童哮喘管理计划继续研究/第二阶段(CAMPCS/2)，这是一项对参加儿童哮喘管理计划(CAMP)的儿童进行的3.25年观察性跟踪研究。CAMP是一项多中心随机临床试验，旨在确定三种治疗方法(单独沙丁胺醇、沙丁胺醇联合吸入皮质类固醇(ICS)、沙丁胺醇联合吸入非类固醇)对1041名轻度哮喘儿童(年龄5-13岁)在3.5-5.5年治疗阶段对肺功能的影响。该队列在为期4.5年的观察阶段(cAMP持续研究，CAMPCS)中进行了跟踪，以确定治疗对肺部的长期影响，并基于国家指南。CAMPCS/2被设计为在队列中再跟随4年，直到成年早期，那时患者将是17-26岁(55%；21岁)。儿童哮喘会在成年后导致严重的肺部疾病，并可能发展为慢性阻塞性肺疾病(COPD)。没有一项对儿童哮喘的长期随访研究需要进行密切的随访，以确定炎性介质对预后的决定因素。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is for the Childhood Asthma Management Program Continuation Study/Phase 2 (CAMPCS/2), A 3.25 year observational follow-up study of the children enrolled in the Childhood Asthma Management Program (CAMP). CAMP was a multicenter randomized clinical trial designed to determine the effects of three treatments (albuterol alone, albuterol with inhaled corticosteroid (ICS), albuterol with inhaled non-steroid) in 1041 children (randomized at ages 5-13 years) with mild asthma on pulmonary function during a 3.5-5.5 year treatment phase. The cohort has been followed in a 4.5 year observational phase (CAMP Continuation Study, CAMPCS) to determine longer term effects of the treatments on lung and based on national guidelines. CAMPCS/2 is designed to follow the cohort for 4 additional years in to early adulthood, when the patients will be 17-26 years (55% >21 years). Childhood asthma can result in significant lung disease in adulthood and possibly the development of chronic obstructive pulmonary disease (COPD). None of the long-term follow-up studies of childhood asthma have had the close follow-up needed to define determinants of outcomes in inflammatory agents on outcomes.